Will patients trust AI to spot prostate cancer? new study investigates

NCT ID NCT07074405

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Liege Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study surveyed 51 men with localized prostate cancer and their healthcare providers in Belgium, Italy, and Spain. The goal was to understand how acceptable artificial intelligence (AI) is as a tool to help diagnose prostate cancer, and whether people are willing to share their health data to develop such AI. Participants filled out an online questionnaire about their views on AI benefits, risks, and their intentions to use it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: questionnaire
What this could lead to: If successful, this research could help design AI tools that patients and doctors trust, improving prostate cancer diagnosis.
What could go wrong: This is a small, completed survey study. It does not test any treatment or AI tool itself, so results may not apply to real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALIZED PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

CHU Liege

Liège, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.